Scarica l'app Stockscreener
67.59
0.81%
0.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca PLC Borsa (AZN) Ultime notizie
Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com
AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360
AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters
AstraZeneca Gets Backing to Trim Fired Worker’s Vaccine Bias Row - Bloomberg Law News
BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK
AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - MarketScreener
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener
Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com
AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance
Nasdaq Bear Market: 3 Unstoppable Stocks You Can Buy With $300 Right Now - The Motley Fool
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com
NICE recommends new combination breast cancer drug - MarketScreener
astrazeneca shareholders approve all resolutions at agm - Investing.com
Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener
AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks
Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com
AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors
GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com
Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo
AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus
AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus
AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News
AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade
AstraZeneca stock touches 52-week low at $61.76 - Investing.com
AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India
UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener
Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener
AstraZeneca (AZN) Prepares for Upcoming Earnings Amid Stock Decl - GuruFocus
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca - Yahoo
FTSE 100 sinks as tariffs kick in with 104% for China; AstraZeneca and GSK slumpMarket Report - Proactive financial news
AstraZeneca's Camizestrant Shows Promise in SERENA-6 Breast Canc - GuruFocus
Trump inflicts £14bn blow to the UK drug sector with tariff threat - Proactive Investors
Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know - Yahoo Finance
Daiichi Sankyo and AstraZeneca get EU approval for Datroway - Seeking Alpha
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
Relative Strength Alert For AstraZeneca - Nasdaq
AstraZeneca PLC (AZN) Stock Price Down 5.81% on Apr 7 - GuruFocus
AstraZeneca Pharma India gets CDSCO nod to import, distribute lung cancer drug Osimertinib - Medical Dialogues
AstraZeneca plc - drugdiscoverytrends.com
AstraZeneca's Innovation Ecosystem: From Blockbusters To Next Generation Of Therapy (AZN) - Seeking Alpha
European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings - AOL.com
AstraZeneca (LSE:AZN) Secures EU Approvals; $125 Million Payment Due to Daiichi Sankyo - Yahoo Finance
AstraZeneca PLC (AZN) Shares Down 6.67% on Apr 4 - GuruFocus
AstraZeneca, AbbVie Lose Minnesota Contract Pharmacy Law Suit - Bloomberg Law News
AstraZeneca’s Imfinzi gets EU nod for lung cancer treatment - Investing.com Australia
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers - Yahoo Finance
AstraZeneca's metastatic breast cancer treatment gets EU nod (AZN:NASDAQ) - Seeking Alpha
AstraZeneca’s Imfinzi gets EU nod for lung cancer treatment By Investing.com - Investing.com South Africa
Omeprazole Market Deep Research Report with Forecast to 2032 | , Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com
Increases to AstraZeneca PLC's (LON:AZN) CEO Compensation Might Cool off for now - simplywall.st
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):